Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by barmac6on Mar 01, 2011 9:39am

260 Views

Post# 18211037

RE: RE: This week.

It would be reassuring to see them exercise the OO below. No doubt they have sat down with management to discuss what to expect from the company for the next several months or years. If they still think $1.53 is good value I may just add to the pile. I guess we will all know within the next 2 weeks.

The company is offering underwriters an overallotment option to buy 784,313 common shares at the same price for another $1,199,998.

Bullboard Posts

Level up your trading with BMO InvestorLine’s enhanced features